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Background. Clinical or microbiological treatment failure and mortality from
Staphylococcus aureus bacteremia (SAB) remains significant. A predictive model was
developed to identify patients at increased risk of treatment failure in order to improve
management strategies.
Methods. Adults with monomicrobial SAB from two prospective observational
cohorts were included. Treatment failure was a composite of all-cause mortality, per-
sistent bacteremia (3 7 days) and recurrent bacteremia within 30 days. Candidate var-
iables were selected a priori based on clinical significance and prior literature, and a
parsimonious model was derived using the Akaike Information Criteria with a com-
plete case analysis. A sum score was derived for clinical use.
Figure 1. Predicted probability of 30-day treatment failure using sum score derived from parsi-
monious predictive model.
Figure 2. Performance of predictive model sum score versus observed 30-day treatment outcome.
Results. Complete data were available for 388 patients, and 20.6% experienced 30-day
treatment failure. The parsimonious multivariable model identified severe sepsis, methi-
cillin-resistant S. aureus (MRSA), patient age, and serum albumin as predictors of treat-
ment failure. Model calibration (Hosmer-Lemeshow test, p = 0.376) and discrimination
(c-statistic 0.752) indicated good performance. A prediction sum score was developed
from this model (Table 1); Figure 1 shows the predicted probability of treatment failure
and Figure 2 shows the sum score according to observed outcomes. The sum score per-
formed well (c-statistic 0.750 compared with the multivariable model).
Conclusion. The combination of severe sepsis, MRSA, older patient age and lower
serum albumin were predictors of 30-day treatment failure. Although some of these
factors are non-modifiable, these are useful indicators for the clinician to ensure the
patient receives early appropriate antibiotics and aggressive supportive care to improve
clinical outcomes.









Severe sepsis 1.29308 1.3 +3
MRSA 0.84871 0.8 +2
Age (per 10 year increment from
age 18 years)
0.3843 0.4 +1
Albumin (per 5 g/L increment
from 10 g/L)
−0.4144 −0.4 −1
*Possible range of score: −7 to +13
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